757977-17-6

Basic information

• Product Name: C₄₉H₅₁NO₁₄
• Synonyms: C₄₉H₅₁NO₁₄
• CAS NO: 757977-17-6
• Molecular Weight: 877.942
• Mol File: 757977-17-6.mol

Chemical Properties

• CAS DataBase Reference: C₄₉H₅₁NO₁₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₄₉H₅₁NO₁₄(757977-17-6)
• EPA Substance Registry System: C₄₉H₅₁NO₁₄(757977-17-6)

Safety Data

• Hazardous Substances Data: 757977-17-6(Hazardous Substances Data)

Upstream product

• 6630-33-7 ortho-bromobenzaldehyde 
• 38018-60-9 (E)-N-(2-bromobenzylidene)-4-methoxyaniline 
• 757977-16-5 3'-dephenyl-3'-(o-allylphenyl)-4-deacetyl-4-acryloyl-7-O-triethylsilyl-2'-O-triisopropylsilylpaclitaxel 
• 860782-19-0 1-dimethylsilyl-4-deacetyl-4-acryloyl-7-O,10-O,13-O-tris-triethylsilylbaccatin III 
• 172482-21-2 4-deacetyl-4-acryloyl-7-O-triethylsilylbaccatin III 
• 860782-21-4 4-deacetyl-4-acryloylbaccatin III 
• 860782-20-3 4-deacetyl-4-acryloyl-10-deacetylbaccatin III 
• 860782-59-8 4-(2-allyl-phenyl)-1-(4-methoxy-phenyl)-3-triisopropylsilanyloxy-azetidin-2-one 
• 860782-81-6 4-(2-bromo-phenyl)-1-(4-methoxy-phenyl)-3-triisopropylsilanyloxy-azetidin-2-one 
• 757977-12-1 4-(2-allyl-phenyl)-3-triisopropylsilanyloxy-azetidin-2-one 
• 941672-61-3 4-(2-bromo-phenyl)-3-hydroxy-1-(4-methoxy-phenyl)-azetidin-2-one 
• 757977-14-3 (3R,4S)-1-benzoyl-3-O-triisopropylsilyloxy-4-(o-allylphenyl)azetidin-2-one 
• 860782-23-6 C₆₄H₈₅NO₁₄Si₂ 

Relevant articles and documents

Evaluation of the tubulin-bound paclitaxel conformation: Synthesis, biology, and SAR studies of C-4 to C-3′ bridged paclitaxel analogues

The important anticancer drug paclitaxel binds to the β-subunit of the ββ-tubulin dimer in the microtubule in a stoichiometric ratio, promoting microtubule polymerization and stability. The conformation of microtubule-bound drug has been the subject of in

CONFORMATIONALLY CONSTRAINED PACLITAXEL ANALOGS AND THEIR USE AS ANTICANCER AND ANTI-ALZHEIMERS AGENTS

Constrained paclitaxel derivatives include a bridge extending from the C-3’ phenyl to either the C4 or -3 positions. Many of the constrained paclitaxel derivatives provide activity comparable or superior to the natural product paclitaxel.